Results 141 to 150 of about 754,069 (334)

Unleashing the Power of Machine Learning in Nanomedicine Formulation Development

open access: yesAdvanced Functional Materials, EarlyView.
A random forest machine learning model is able to make predictions on nanoparticle attributes of different nanomedicines (i.e. lipid nanoparticles, liposomes, or PLGA nanoparticles) based on microfluidic formulation parameters. Machine learning models are based on a database of nanoparticle formulations, and models are able to generate unique solutions
Thomas L. Moore   +7 more
wiley   +1 more source

Citation [PDF]

open access: yes, 2015
Robitaille, Jean-Pierre   +1 more
openaire   +2 more sources

Bioengineering a Patient‐Derived Vascularized Lung Tumor‐on‐Chip Model to Decipher Immunomodulation by the Endothelium

open access: yesAdvanced Healthcare Materials, EarlyView.
Most in vitro cancer models lack cellular diversity, functional complexity, and clinical relevance. This work highlights the generation of an innovative dynamic tetraculture with autologous patient‐derived cells within a vascularized tumor‐on‐chip, as well as the recapitulation of endothelial anergy features induced by the tumor microenvironment ...
Christine Lansche   +16 more
wiley   +1 more source

A response to Poisot et al.: Publishing your dataset is not always virtuous

open access: yesIdeas in Ecology and Evolution, 2013
n ...
Angela Moles   +2 more
doaj  

Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents a targeted mRNA‐LNP platform engineered with anti‐PSMA nanobodies for prostate cancer therapy. Using different in vivo models, the authors demonstrate selective uptake and mRNA delivery in PSMA+ cancer cells. However, while targeting is enhanced, mRNA delivery efficacy is limited by tissue penetration, tumor necrosis, and immune ...
Pol Escudé Martinez de Castilla   +16 more
wiley   +1 more source

A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity

open access: yesAdvanced Healthcare Materials, EarlyView.
A new oxaliplatin‐based Pt(IV) prodrug bearing a Mn(II) superoxide dismutase mimic is synthesized and studied, in vitro and in vivo, in the context of colorectal cancer. Encapsulation of this prodrug in an easy‐to‐implement PEGylated micelle formulation demonstrated the highest in vivo anticancer activity among all the tested conditions, supporting the
Alvaro Lopez‐Sanchez   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy